Surgery Partners or Tenet Healthcare: Which Stock Has More Upside?
Tenet Healthcare fell -11% during the past Week. You may be tempted to buy more, or may want to reduce your exposure. But there is an entirely different perspective you might be missing. Is there a better alternative? Turns out, its peer Surgery Partners gives you more. Surgery Partners (SGRY) stock offers superior revenue growth across key periods, better profitability, and relatively lower valuation vs Tenet Healthcare (THC) stock, suggesting you may be better off investing in SGRY
- SGRY’s Last 12 Months revenue growth was 6.2%, vs. THC’s 3.1%.
- In addition, its Last 3-Year Average revenue growth came in at 9.3%, ahead of THC’s 3.6%.
- SGRY’s 3-year average margin is stronger: 14.6% vs. THC’s 14.0%.
These differences become even clearer when you look at the financials side by side. The table highlights how THC’s fundamentals stack up against those of SGRY on growth, margins, momentum, and valuation multiples.
Valuation & Performance Overview
| THC | SGRY | Preferred | |
|---|---|---|---|
| Valuation | |||
| P/EBIT Ratio | 5.4 | 3.4 | SGRY |
| Revenue Growth | |||
| Last Quarter | 8.9% | 2.4% | THC |
| Last 12 Months | 3.1% | 6.2% | SGRY |
| Last 3 Year Average | 3.6% | 9.3% | SGRY |
| Operating Margins | |||
| Last 12 Months | 16.1% | 14.2% | THC |
| Last 3 Year Average | 14.0% | 14.6% | SGRY |
| Momentum | |||
| Last 3 Year Return | 284.4% | -59.5% | THC |
Note: For “Last 3 Year Return” metric, preferred stock is one with higher returns unless the returns are too high (>300%) which creates risk of sell off.
See more revenue details: THC Revenue Comparison | SGRY Revenue Comparison
See more margin details: THC Operating Income Comparison | SGRY Operating Income Comparison
- Better Value & Growth: DELL Leads Apple Stock
- Wheaton’s Pullback: Temporary Noise Or Real Opportunity?
- Get Paid 9.8% to Buy CRM at a 30% Discount – Here’s How
- The Credibility Gap: Why Carvana’s Best Quarter In Years Led To Its Steepest Sell-Off
- Adobe Stock: Strong Cash Flow Poised for a Re-Rating?
- Microsoft Stock Pays Out $376 Bil – Investors Take Note
See detailed fundamentals on Buy or Sell THC Stock. Below we compare market return and related metrics across years.
Historical Market Performance
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | Avg | Best | |
|---|---|---|---|---|---|---|---|---|---|
| Returns | |||||||||
| THC Return | 105% | -40% | 55% | 67% | 57% | 10% | 449% | <=== | |
| SGRY Return | 84% | -48% | 15% | -34% | -27% | -20% | -57% | ||
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -2% | 78% | ||
| Monthly Win Rates [3] | |||||||||
| THC Win Rate | 92% | 33% | 67% | 67% | 75% | 33% | 61% | <=== | |
| SGRY Win Rate | 67% | 42% | 50% | 42% | 33% | 33% | 44% | ||
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 33% | 60% | ||
| Max Drawdowns [4] | |||||||||
| THC Max Drawdown | -2% | -54% | 0% | -2% | -13% | -5% | -13% | ||
| SGRY Max Drawdown | -5% | -58% | -20% | -39% | -29% | -20% | -28% | ||
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -3% | -8% | <=== | |
[1] Cumulative total returns since the beginning of 2021
[2] 2026 data is for the year up to 3/17/2026 (YTD)
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
No matter how good the numbers, stock investment is never a smooth ride. There is a risk you must factor in. Read SGRY Dip Buyer Analyses and THC Dip Buyer Analyses to see how these stocks have fallen and recovered in the past.
Still not sure about THC or SGRY? Consider portfolio approach.
Smart Investing Begins With Portfolios
Stocks can jump or crash but long term success comes from staying invested. The right portfolio helps you ride gains and cushion single stock drops.
The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? HQ Portfolio has posted more than 105% in cumulative return since inception, with less risk versus the benchmark index, as evident in HQ Portfolio performance metrics.